Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. increased its position in Evolus, Inc. (NASDAQ:EOLS) by 31.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,056 shares of the company’s stock after acquiring an additional 4,803 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Evolus were worth $211,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. China Universal Asset Management Co. Ltd. grew its holdings in shares of Evolus by 353.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,614 shares of the company’s stock worth $70,000 after acquiring an additional 5,155 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in shares of Evolus by 13.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 12,345 shares of the company’s stock worth $113,000 after acquiring an additional 1,484 shares during the period. Teza Capital Management LLC acquired a new stake in shares of Evolus in the 3rd quarter worth approximately $136,000. Kestra Advisory Services LLC grew its holdings in shares of Evolus by 18.5% in the 3rd quarter. Kestra Advisory Services LLC now owns 16,356 shares of the company’s stock worth $149,000 after acquiring an additional 2,550 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Evolus in the 3rd quarter worth approximately $171,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Stock Down 0.3 %

Shares of Evolus stock opened at $11.43 on Friday. Evolus, Inc. has a fifty-two week low of $7.07 and a fifty-two week high of $15.43. The firm has a market cap of $662.25 million, a PE ratio of -10.49 and a beta of 1.45. The business’s fifty day moving average is $13.39 and its two-hundred day moving average is $11.25.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). The business had revenue of $61.00 million during the quarter, compared to the consensus estimate of $61.14 million. Equities research analysts anticipate that Evolus, Inc. will post -0.51 EPS for the current year.

Insiders Place Their Bets

In other Evolus news, Director Karah Herdman Parschauer sold 11,931 shares of the stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $13.14, for a total transaction of $156,773.34. Following the transaction, the director now owns 31,243 shares of the company’s stock, valued at approximately $410,533.02. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Evolus news, insider Rui Avelar sold 27,603 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total value of $384,233.76. Following the transaction, the insider now directly owns 372,288 shares of the company’s stock, valued at $5,182,248.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Karah Herdman Parschauer sold 11,931 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $13.14, for a total value of $156,773.34. Following the completion of the transaction, the director now directly owns 31,243 shares in the company, valued at $410,533.02. The disclosure for this sale can be found here. Insiders have sold a total of 60,969 shares of company stock valued at $831,005 in the last quarter. 5.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have commented on EOLS shares. Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Evolus in a report on Wednesday, April 10th. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Evolus in a report on Friday, March 1st. Finally, Barclays upgraded Evolus from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $10.00 to $16.00 in a report on Monday, January 29th.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.